<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.113173</article-id><article-id pub-id-type="publisher-id">ACM-41100</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210300000_44105238.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  75例乳腺包裹性乳头状癌的临床特征及预后分析
  Analysis of Clinical Characteristics and Prognosis of 75 Cases of Encapsulated Papillary Carcinoma
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>凯迪</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>文凤</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院乳腺病诊疗中心，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>1199</fpage><lpage>2105</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨乳腺包裹性乳头状癌的临床特征、治疗方式及预后。方法：应用医渡云科研大数据系统(YIDUCLOUD)收集2012年3月至2018年12月青岛大学附属医院收治的75例经手术病理确诊为乳腺包裹性乳头状癌患者的临床资料。结果：75例患者中，女性72例，男性3例，中位发病年龄63岁。原发肿瘤中位大小为2.0 cm。所有患者均行手术治疗。腋窝淋巴结清扫的患者中转移者7例，均为乳腺包裹性乳头状癌伴浸润性癌的患者。中位随访时间43个月(范围：12~93个月)，失访6例。5年总生存率为93.7%，5年无病生存率为89.9%。结论：乳腺包裹性乳头状癌是一种极为少见的低度恶性乳腺癌，以手术治疗为主，预后较好。对于伴浸润性癌的包裹性乳头状癌患者建议行前哨淋巴结活检。
    Objective: To investigate the clinical characteristics, treatment, and prognostic of Encapsulated papillary carcinoma (EPC). Methods: Data of 75 EPC confirmed by operation and pathology patients hospitalized in the Affiliated Hospital of Qingdao University from March 2012 to December 2018 was collected from the YIDUCLOUD system. Results: Of the 75 patients, there were 72 females and 3 males. The median age was 63 years old. The median size of primary tumor was 2.0 cm. All patients received surgical treatment. Among the patients with axillary lymph node dissection, seven of whom had lymph node metastasis. The patients with positive lymph nodes were all cases of EPC associated with invasive carcinoma. The median follow-up time was 43 months (range: 12~93 months), and 6 cases failed to follow up. The 5-year overall survival and disease-free survival rates were 93.7% and 89.9%. Conclusions: EPC is a rare low grade malignant breast cancer, which is mainly treated by surgery and has a good prognosis. We recommend offering sentinel node evaluation to EPC with invasive carcinoma. 
  
 
</p></abstract><kwd-group><kwd>乳腺癌，包裹性乳头状癌，临床特征，治疗，预后, Breast Cancer</kwd><kwd> Encapsulated Papillary Carcinoma</kwd><kwd> Clinical Characteristic</kwd><kwd> Treatment</kwd><kwd> Prognosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨乳腺包裹性乳头状癌的临床特征、治疗方式及预后。方法：应用医渡云科研大数据系统(YIDUCLOUD)收集2012年3月至2018年12月青岛大学附属医院收治的75例经手术病理确诊为乳腺包裹性乳头状癌患者的临床资料。结果：75例患者中，女性72例，男性3例，中位发病年龄63岁。原发肿瘤中位大小为2.0 cm。所有患者均行手术治疗。腋窝淋巴结清扫的患者中转移者7例，均为乳腺包裹性乳头状癌伴浸润性癌的患者。中位随访时间43个月(范围：12~93个月)，失访6例。5年总生存率为93.7%，5年无病生存率为89.9%。结论：乳腺包裹性乳头状癌是一种极为少见的低度恶性乳腺癌，以手术治疗为主，预后较好。对于伴浸润性癌的包裹性乳头状癌患者建议行前哨淋巴结活检。</p></sec><sec id="s2"><title>关键词</title><p>乳腺癌，包裹性乳头状癌，临床特征，治疗，预后</p></sec><sec id="s3"><title>Analysis of Clinical Characteristics and Prognosis of 75 Cases of Encapsulated Papillary Carcinoma</title><p>Kaidi Li<sup>*</sup>, Wenfeng Li<sup>#</sup></p><p>Breast Disease Center, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/56-1572012x4_hanspub.png" /></p><p>Received: Feb. 17<sup>th</sup>, 2021; accepted: Mar. 5<sup>th</sup>, 2021; published: Mar. 22<sup>nd</sup>, 2021</p><p><img src="//html.hanspub.org/file/56-1572012x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the clinical characteristics, treatment, and prognostic of Encapsulated papillary carcinoma (EPC). Methods: Data of 75 EPC confirmed by operation and pathology patients hospitalized in the Affiliated Hospital of Qingdao University from March 2012 to December 2018 was collected from the YIDUCLOUD system. Results: Of the 75 patients, there were 72 females and 3 males. The median age was 63 years old. The median size of primary tumor was 2.0 cm. All patients received surgical treatment. Among the patients with axillary lymph node dissection, seven of whom had lymph node metastasis. The patients with positive lymph nodes were all cases of EPC associated with invasive carcinoma. The median follow-up time was 43 months (range: 12~93 months), and 6 cases failed to follow up. The 5-year overall survival and disease-free survival rates were 93.7% and 89.9%. Conclusions: EPC is a rare low grade malignant breast cancer, which is mainly treated by surgery and has a good prognosis. We recommend offering sentinel node evaluation to EPC with invasive carcinoma.</p><p>Keywords:Breast Cancer, Encapsulated Papillary Carcinoma, Clinical Characteristic, Treatment, Prognosis</p><disp-formula id="hanspub.41100-formula36"><graphic xlink:href="//html.hanspub.org/file/56-1572012x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/56-1572012x8_hanspub.png" /> <img src="//html.hanspub.org/file/56-1572012x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>乳腺包裹性乳头状癌(Encapsulated papillary carcinoma, EPC)，又称囊内乳头状癌。是临床上一种十分罕见的乳腺癌，约占所有乳腺癌的0.5%~2% [<xref ref-type="bibr" rid="hanspub.41100-ref1">1</xref>]，可发生于任何年龄的女性，多见于绝经后女性，该病预后较好。本研究中，我们回顾性分析了2012~2018年间青岛大学附属医院收治的75例EPC患者的临床资料，目的是探讨EPC的临床特征、治疗和预后。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>通过医渡云数据平台收集了青岛大学附属医院乳腺疾病诊疗中心于2012年1月至2018年12月间确诊为EPC的75例患者的临床资料，其中单纯EPC 19例，EPC伴浸润性癌39例，EPC伴导管原位癌17例，如表1所示。</p></sec><sec id="s6_2"><title>2.2. 研究方法</title><p>分析患者的临床特征，如患者的年龄、性别、月经状态、肿瘤家族史、肿瘤大小、淋巴结转移状态、有无远处转移，免疫组织化学检测情况和治疗。根据2013年《St.Gallen共识》将乳腺癌进行分子分型：1) Luminal A型：ER(+)，PR(+)，HER-2(−)，Ki-67 ≤ 14%；2) Luminal B型：ER(+)，PR(+)，HER-2(−)，Ki-67 &gt; 14%；ER(+)，HER-2(+)；3) HER-2阳性型：ER(−)，PR(−)，HER-2(+)；4) 三阴型：ER、PR、HER-2均为(−)。</p></sec><sec id="s6_3"><title>2.3. 随访</title><p>对75例EPC患者通过门诊复查或电话随访的方式进行随访，其中失访6例。随访截至患者死亡或2019年12月31日。无病生存时间为疾病确诊日期至首次出现复发或转移的时间或至死亡或随访终止。总生存时间为疾病确诊日期至死亡或随访终止。</p></sec><sec id="s6_4"><title>2.4. 统计学分析</title><p>统计学分析采用SPSS 25.0软件。生存分析采用Kaplan-Meier法，比较组间差异采用Log-Rank秩检验，并绘制生存曲线。P &lt; 0.05被认为具有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 临床特征</title><p>75例患者的中位年龄为63岁(范围36~89岁)；女性72例，其中绝经女性58例，未绝经女性14例；男性3例；41例为左侧乳腺，34例为右侧乳腺；68例患者的初发症状为乳房肿块(90.7%)，2例患者为乳头溢液(2.7%)，5例患者为肿块伴有乳头溢液(6.7%)。原发肿瘤中位大小2.0 cm (范围0.5~6 cm)。2例(2.7%)患者有乳腺癌家族史。ER、PR、HER-2表达阳性的患者分别为72例(96.0%)，71例(94.7%)，2例(2.7%)。Luminal A型、Luminal B型、HER-2阳性型、三阴型分别为47例(62.7%)，25例(33.3%)，1例(1.3%)，2例(2.7%)。术后病理结果示单纯EPC、EPC伴浸润性癌、EPC伴导管原位癌分别为19例(25.3%)，39例(52.0%)，17例(22.7%)。</p></sec><sec id="s7_2"><title>3.2. 治疗方法</title><p>本研究所有患者均行外科手术治疗，其中30例(40.0%)行全乳房单纯切除术；25例(33.3%)行乳腺癌改良根治术；20例(26.7%)行保乳手术，其中6例接受了术后辅助放射治疗。35例(46.7%)进行前哨淋巴结切除活检；27例患者(36.0%)行腋窝淋巴结清扫，其中病理证实腋窝淋巴结转移7例，且均为EPC伴浸润性癌的患者；59例激素受体阳性的(78.7%)患者接受了内分泌治疗；8例(11.6%)接受了化学治疗，其中5例为EPC伴浸润性癌，2例为EPC伴导管原位癌，1例为单纯EPC。</p></sec><sec id="s7_3"><title>3.3. 生存分析</title><p>本组75例患者中位随访时间43个月(范围：12~93个月)。至随访截止日，1例患者发生骨转移，2例患者死亡，死因均与乳腺相关性疾病无关(1例因慢性肾功能衰竭死亡，另1例死因子宫平滑肌肉瘤死亡)。5年总生存率为93.7%，5年无病生存率为89.9%，见图1。乳腺包裹性乳头状癌的预后较好，由于本研究样本量较小，随访时间较短，且2例死亡患者均死于其他疾病，因此未进行预后的单因素和多因素分析。</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Clinicopathological characteristics of 75 patients with breast intracystic papillary carcinom</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" >临床特征</th><th align="center" valign="middle" >例数n (%)</th></tr></thead><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;40</td><td align="center" valign="middle" >1 (1.3)</td></tr><tr><td align="center" valign="middle" >40~60</td><td align="center" valign="middle" >31 (41.3)</td></tr><tr><td align="center" valign="middle" >&gt;60</td><td align="center" valign="middle" >43 (57.3)</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >肿瘤家族史</th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >8 (10.7)</td></tr><tr><td align="center" valign="middle" >无</td><td align="center" valign="middle" >67 (89.3)</td></tr><tr><td align="center" valign="middle" >初发症状</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >肿块</td><td align="center" valign="middle" >68 (90.7)</td></tr><tr><td align="center" valign="middle" >乳头溢液</td><td align="center" valign="middle" >2 (2.7)</td></tr><tr><td align="center" valign="middle" >肿块伴乳头溢液</td><td align="center" valign="middle" >5 (6.7)</td></tr><tr><td align="center" valign="middle" >月经情况</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >绝经</td><td align="center" valign="middle" >58 (77.3)</td></tr><tr><td align="center" valign="middle" >未绝经</td><td align="center" valign="middle" >14 (18.7)</td></tr><tr><td align="center" valign="middle" >T分期</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >T1</td><td align="center" valign="middle" >55 (73.3)</td></tr><tr><td align="center" valign="middle" >T2</td><td align="center" valign="middle" >19 (25.3)</td></tr><tr><td align="center" valign="middle" >T3</td><td align="center" valign="middle" >1 (1.3)</td></tr><tr><td align="center" valign="middle" >T4</td><td align="center" valign="middle" >0 (0.0)</td></tr><tr><td align="center" valign="middle" >腋窝淋巴结转移</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >是</td><td align="center" valign="middle" >7 (9.3)</td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >68 (90.7)</td></tr><tr><td align="center" valign="middle" >ER</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >72 (96.0)</td></tr><tr><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >3 (4.0)</td></tr><tr><td align="center" valign="middle" >PR</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >71 (94.7)</td></tr><tr><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >4 (5.3)</td></tr><tr><td align="center" valign="middle" >HER-2</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >2 (2.7)</td></tr><tr><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >73 (97.3)</td></tr><tr><td align="center" valign="middle" >Ki-67</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≤14%</td><td align="center" valign="middle" >47 (62.6)</td></tr><tr><td align="center" valign="middle" >&gt;14%</td><td align="center" valign="middle" >28 (37.3)</td></tr><tr><td align="center" valign="middle" >手术方式</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >乳房单纯切除术</td><td align="center" valign="middle" >30 (40.0)</td></tr><tr><td align="center" valign="middle" >乳腺癌改良根治术</td><td align="center" valign="middle" >25 (33.3)</td></tr><tr><td align="center" valign="middle" >保乳术</td><td align="center" valign="middle" >20 (26.7)</td></tr><tr><td align="center" valign="middle" >腋窝淋巴结手术</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >腋窝淋巴结清扫术</td><td align="center" valign="middle" >27 (36.0)</td></tr></tbody></table></table-wrap><table-wrap id="1_3"><table><tbody><thead><tr><th align="center" valign="middle" >前哨淋巴结活检术</th><th align="center" valign="middle" >35 (46.7)</th></tr></thead><tr><td align="center" valign="middle" >分子分型</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Luminal A型</td><td align="center" valign="middle" >47 (62.7)</td></tr><tr><td align="center" valign="middle" >Luminal B型</td><td align="center" valign="middle" >25 (33.3)</td></tr><tr><td align="center" valign="middle" >HER-2阳性型</td><td align="center" valign="middle" >1 (1.3)</td></tr><tr><td align="center" valign="middle" >三阴型</td><td align="center" valign="middle" >2 (2.7)</td></tr><tr><td align="center" valign="middle" >病理状态</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >单纯包裹性乳头状癌</td><td align="center" valign="middle" >19 (25.3)</td></tr><tr><td align="center" valign="middle" >包裹性乳头状癌伴浸润</td><td align="center" valign="middle" >39 (52.0)</td></tr><tr><td align="center" valign="middle" >包裹性乳头状癌伴原位癌</td><td align="center" valign="middle" >17 (22.7)</td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. 75例乳腺包裹性乳头状癌患者的基线临床特征</p><p>图1. 75例乳腺包裹性乳头状癌患者的生存曲线。(a) 总生存；(b) 无病生存</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>乳腺包裹性乳头状癌是一种十分罕见且类型特殊的乳腺癌，老年女性发病率高，也可见于男性，但文献中多以个案的形式被报道 [<xref ref-type="bibr" rid="hanspub.41100-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.41100-ref3">3</xref>]。75例患者中位发病年龄63岁，女性72例，男性3例，与之相符。其初发症状为可触及的乳房肿块，伴或不伴乳头溢液，原发肿瘤中位大小2.0 cm，与之前的研究基本一致 [<xref ref-type="bibr" rid="hanspub.41100-ref4">4</xref>]。EPC最初被Carter [<xref ref-type="bibr" rid="hanspub.41100-ref5">5</xref>] 等描述为导管内癌的一种变异类型，之后有研究 [<xref ref-type="bibr" rid="hanspub.41100-ref6">6</xref>] 发现，肿瘤囊壁周围肌上皮细胞表达缺失，说明EPC具有侵袭性。目前大多数学者认为其可能是介于原位癌与浸润性癌之间的一种疾病类型 [<xref ref-type="bibr" rid="hanspub.41100-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.41100-ref8">8</xref>]。</p><p>EPC的临床表现和影像学检查缺乏特异性，且术前穿刺活检很难对EPC进行准确的病理诊断，容易被误诊为乳腺良性病变或乳腺其他肿瘤，必要时需要手术切除肿块来明确诊断。临床医师对于EPC的临床治疗仍缺乏共识，不同治疗方法均有报道。外科手术切除是目前该病的主要治疗方法，但要保证阴性的切缘 [<xref ref-type="bibr" rid="hanspub.41100-ref9">9</xref>]。有研究 [<xref ref-type="bibr" rid="hanspub.41100-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.41100-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.41100-ref12">12</xref>] 发现保乳手术组和乳房全切组总生存率的差异无统计学意义，因此保乳手术和乳房全切除术均可作为EPC的手术方法。本组患者全部接受手术治疗，其中55例行乳房全切术，25例行保乳手术。值得注意的是，本研究中3例男性患者均行乳房全切术，我们认为男性可参照女性的手术处理原则，但保乳手术主要针对女性。SEER数据库 [<xref ref-type="bibr" rid="hanspub.41100-ref13">13</xref>] 进行的一项大型数据分析证实了EPC保乳术后辅助放射治疗的益处，白种人和接受放射治疗的患者的生存率都有所提高。所以应该建议保乳手术的EPC患者术后辅助放射治疗。本组20例保乳术后患者中，6例行辅助放射治疗。75例患者中，ER、PR、HER-2表达阳性者分别为72例、71例、2例，其中内分泌治疗被应用于59例激素受体阳性的患者，8例接受化学治疗的患者中6例为EPC伴浸润。可以看出，本组患者大多数是激素受体阳性，与之前的文献报道相一致 [<xref ref-type="bibr" rid="hanspub.41100-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.41100-ref14">14</xref>]。有研究 [<xref ref-type="bibr" rid="hanspub.41100-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.41100-ref13">13</xref>] 表明EPC患者可进行适当的激素治疗，但目前尚没有研究证实EPC患者是否从内分泌治疗中获益。</p><p>75例患者按照病理状态不同，分为单纯EPC 19例，EPC伴浸润性癌39例，EPC伴导管原位癌17例。Grabowski等 [<xref ref-type="bibr" rid="hanspub.41100-ref1">1</xref>] 研究发现，伴有原位癌与伴有浸润性癌的EPC患者之间的10年相对生存率无明显差异，均&gt;90%。无论是单纯EPC，还是伴有浸润或原位癌，预后都很好，极少累及区域淋巴结。值得注意的是，本组患者7例腋窝淋巴结转移者和1例骨转移者的病理状态均为EPC伴浸润性癌，腋窝淋巴结阳性的研究结果与之前文献报道 [<xref ref-type="bibr" rid="hanspub.41100-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.41100-ref10">10</xref>] 相似。亦有研究 [<xref ref-type="bibr" rid="hanspub.41100-ref15">15</xref>] 报道，淋巴结转移在EPC伴浸润的患者中更为常见。另有一些研究显示，即使在单纯性EPC患者中，淋巴结也会发生转移 [<xref ref-type="bibr" rid="hanspub.41100-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.41100-ref17">17</xref>]。然而，目前还没有研究将淋巴结状况与EPC患者的生存期联系起来。为了避免过度治疗，我们可通过前哨淋巴结活检的方式来评估腋窝淋巴结状态，以明确EPC患者的临床分期。前哨淋巴结活检可能是EPC患者全腋窝淋巴结清扫的一个很好的替代方法 [<xref ref-type="bibr" rid="hanspub.41100-ref18">18</xref>]。</p><p>本组患者5年总生存率为93.7%，5年无病生存率为89.9%。随访过程中，有2例高龄(≥84岁) EPC患者死亡，均同时患有多种基础疾病，且均死于非EPC相关疾病。且多项研究 [<xref ref-type="bibr" rid="hanspub.41100-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.41100-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.41100-ref13">13</xref>] 报道，EPC患者预后良好。由于EPC患者预后较好，发病率低，进一步研究其治疗和预后需要更长时间以及更大样本量的随访观察。治疗上，我们建议单纯EPC的治疗可按导管原位癌处理，以避免过度治疗；而对于伴浸润性癌的EPC，可进行前哨淋巴结活检，以明确肿瘤分期，制定个体化治疗方案，从而有利于患者的预后。</p></sec><sec id="s9"><title>声明</title><p>该文病例报道获得病人的知情同意。</p></sec><sec id="s10"><title>文章引用</title><p>李凯迪,李文凤. 75例乳腺包裹性乳头状癌的临床特征及预后分析Analysis of Clinical Characteristics and Prognosis of 75 Cases of Encapsulated Papillary Carcinoma[J]. 临床医学进展, 2021, 11(03): 1199-2105. https://doi.org/10.12677/ACM.2021.113173</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41100-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Grabowski, J., Salzstein, S.L., Sadler, G.R. and Blair, S. (2008) Intracystic Papillary Carcinoma: A Review of 917 Cases. Cancer, 113, 916-920. &lt;br&gt;https://doi.org/10.1002/cncr.23723</mixed-citation></ref><ref id="hanspub.41100-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">陈中, 陈建华, 丁博. 男性原发乳腺包裹性乳头状癌1例[J]. 诊断病理学杂志, 2019, 26(9): 627-628.</mixed-citation></ref><ref id="hanspub.41100-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Kinoshita, H., Kashiwagi, S., Teraoka, H., et al. (2018) Intracystic Papillary Carcinoma of the Male Breast: A Case Report. World Journal of Surgical Oncology, 16, 15. &lt;br&gt;https://doi.org/10.1186/s12957-018-1318-5</mixed-citation></ref><ref id="hanspub.41100-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Hassan, Z., Boulos, F., Abbas, J., et al. (2020) Intracystic Papillary Carcinoma: Clinical Presentation, Patterns of Practice, and Oncological Outcomes. Breast Cancer Research and Treatment, 182, 317-323.  
&lt;br&gt;https://doi.org/10.1007/s10549-020-05680-9</mixed-citation></ref><ref id="hanspub.41100-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Carter, D. (1977) Intraductal Papillary Tumors of the Breast: A Study of 78 Cases. Cancer, 39, 1689-1692.  
&lt;br&gt;https://doi.org/10.1002/1097-0142(197704)39:4&lt;1689::AID-CNCR2820390444&gt;3.0.CO;2-L</mixed-citation></ref><ref id="hanspub.41100-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Hill, C.B. and Yeh, I.T. (2005) Myoepithelial Cell Staining Patterns of Papillary Breast Lesions: From Intraductal Papillomas to Invasive Papillary Carcinomas. American Journal of Clinical Pathology, 123, 36-44.  
&lt;br&gt;https://doi.org/10.1309/XG7TPQ16DMJAV8P1</mixed-citation></ref><ref id="hanspub.41100-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Collins, L.C., Carlo, V.P., Hwang, H., et al. (2006) Intracystic Papillary Carcinomas of the Breast: A Reevaluation Using a Panel of Myoepithelial Cell Markers. The American Journal of Surgical Pathology, 30, 1002-1007.  
&lt;br&gt;https://doi.org/10.1097/00000478-200608000-00011</mixed-citation></ref><ref id="hanspub.41100-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Li, X., Xu, Y., Ye, H., et al. (2018) Encapsulated Papillary Carcinoma of the Breast: A Clinicopathological Study of 49 Cases. Current Problems in Cancer, 42, 291-301. &lt;br&gt;https://doi.org/10.1016/j.currproblcancer.2018.03.005</mixed-citation></ref><ref id="hanspub.41100-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Stamatakos, M., Stefanaki, C., Stasinou, T., et al. (2011) Intracystic Papillary Carcinoma of the Breast in Males. In Search of the Optimal Treatment for this Rare Disease. Breast Care, 6, 399-403. &lt;br&gt;https://doi.org/10.1159/000331386</mixed-citation></ref><ref id="hanspub.41100-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Solorzano, C.C., Middleton, L.P., Hunt, K.K., et al. (2002) Treatment and Outcome of Patients with Intracystic Papillary Carcinoma of the Breast. The American Journal of Surgery, 184, 364-368.  
&lt;br&gt;https://doi.org/10.1016/S0002-9610(02)00941-8</mixed-citation></ref><ref id="hanspub.41100-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Fayanju, O.M., Ritter, J., Gillanders, W.E., et al. (2007) Therapeutic Management of Intracystic Papillary Carcinoma of the Breast: The Roles of Radiation and Endocrine Therapy. The American Journal of Surgery, 194, 497-500.  
&lt;br&gt;https://doi.org/10.1016/j.amjsurg.2007.06.016</mixed-citation></ref><ref id="hanspub.41100-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">吕民豪, 秦丽, 李军涛, 等. 乳腺囊内乳头状癌: 49例临床特征及预后分析[J]. 肿瘤, 2016, 36(8): 896-900.</mixed-citation></ref><ref id="hanspub.41100-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Mogal, H., Brown, D.R., Isom, S., et al. (2016) Intracystic Papillary Carcinoma of the Breast: A SEER Database Analysis of Implications for Therapy. The Breast, 27, 87-92. &lt;br&gt;https://doi.org/10.1016/j.breast.2016.01.003</mixed-citation></ref><ref id="hanspub.41100-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">郭佳, 白雪峰. 乳腺包裹性乳头状癌35例临床病理特征分析[J]. 诊断病理学杂志, 2020, 27(4): 233-236.</mixed-citation></ref><ref id="hanspub.41100-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Wynveen, C.A., Nehhozina, T., Akram, M., et al. (2011) Intracystic Papillary Carcinoma of the Breast: An in Situ or Invasive Tumor? Results of Immunohistochemical Analysis and Clinical Follow-Up. The American Journal of Surgical Pathology, 35, 1-14. &lt;br&gt;https://doi.org/10.1097/PAS.0b013e3181fbe20a</mixed-citation></ref><ref id="hanspub.41100-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Esposito, N.N., Dabbs, D.J. and Bhargava, R. (2009) Are Encapsulated Papillary Carcinomas of the Breast in Situ or Invasive? A Basement Membrane Study of 27 Cases. American Journal of Clinical Pathology, 131, 228-242.  
&lt;br&gt;https://doi.org/10.1309/AJCP8A2UVLCYGTPU</mixed-citation></ref><ref id="hanspub.41100-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Mulligan, A.M. and O’Malley, F.P. (2007) Metastatic Potential of Encapsulated (Intracystic) Papillary Carcinoma of the Breast: A Report of 2 Cases with Axillary Lymph Node Micrometastases. International Journal of Surgical Pathology, 15, 143-147. &lt;br&gt;https://doi.org/10.1177/1066896906299119</mixed-citation></ref><ref id="hanspub.41100-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, J., Zhang, T., Wu, N., et al. (2018) Intracystic Papillary Carcinoma of the Breast: Experience of a Major Chinese Cancer Center. Pathology—Research and Practice, 214, 579-585. &lt;br&gt;https://doi.org/10.1016/j.prp.2018.01.006</mixed-citation></ref></ref-list></back></article>